Cardiotoxicities of breast cancer treatment.
Department of Physiological Nursing, University of California, San Francisco, USA.
Pamela Hallquist
PH
Viale
Deanna Sanchez
DS
Yamamoto
D018943:Anthracyclines / Q000627:therapeutic use / Q000633:toxicity; D000911:Antibodies, Monoclonal / Q000627:therapeutic use / Q000633:toxicity; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use / Q000633:toxicity*; D047072:Aromatase Inhibitors / Q000627:therapeutic use / Q000633:toxicity; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000451:nursing*; D054715:Cardiotoxins / Q000627:therapeutic use / Q000633:toxicity*; D005260:Female; D006321:Heart / Q000187:drug effects*; D006801:Humans; D043823:Taxoids / Q000627:therapeutic use / Q000633:toxicity; D000068878:Trastuzumab
D018943:Anthracyclines; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D047072:Aromatase Inhibitors; D054715:Cardiotoxins; D043823:Taxoids; D000068878:Trastuzumab